Apolipoprotein A-I (APOA1) Antibody
260€ (100 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Name
Apolipoprotein A-I (APOA1) Antibody
Category
Primary Antibodies
Provider
Abbexa
Reference
abx131726
Tested Applications
WB
Description
Apolipoprotein A-I Antibody is a Mouse Monoclonal against Apolipoprotein A-I.
Documentos del producto
Instrucciones
Data sheet
Especificaciones del producto
| Category | Primary Antibodies |
| Immunogen Target | Target: Apolipoprotein A-I (APOA1) Immunogen: Gln122-Gln267 |
| Host | Mouse |
| Reactivity | Human |
| Recommended Dilution | WB: 0.01-5 µg/ml, IHC (Predicted): 5-30 µg/ml, IF/ICC (Predicted): 5-30 µg/ml. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | Unconjugated |
| Isotype | IgG2b Kappa |
| Purification | Purified by Protein A and Protein G affinity chromatography. |
| Size 1 | 100 µl |
| Size 2 | 200 µl |
| Size 3 | 1 ml |
| Form | Liquid |
| Tested Applications | WB |
| Buffer | 0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol. |
| Availability | Shipped within 5-7 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | P02647 |
| Gene ID | 335 |
| NCBI Accession | NP_000030.1 |
| OMIM | 105200 |
| Alias | Apo A1,Apo-A1,apo(a), apolipoprotein A1, Apolipoprotein A-I,HPALP2,APOA1,Apolipoprotein AI |
| Background | Antibody anti-APOA1 |
| Status | RUO |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. |
Background
APOA1 is the primary protein component of high-density lipoprotein (HDL), often referred to as "good cholesterol," where it plays a crucial role in reverse cholesterol transport. APOA1 facilitates the removal of cholesterol from peripheral tissues and delivers it to the liver for excretion via bile, thus protecting against atherosclerosis and cardiovascular disease. APOA1 is also an activator of lecithin-cholesterol acyltransferase (LCAT), an enzyme critical for HDL maturation and cholesterol esterification. Mutations in the APOA1 gene can result in familial HDL deficiency or amyloidosis, leading to cardiovascular dysfunction and systemic deposits of amyloid fibrils. As a key modulator of lipid metabolism, APOA1 is a major therapeutic target for managing dyslipidemia and reducing cardiovascular risk.